Liver Cancer Podcast

Season 3 - Episode 10 In this episode, Dr. Manon Allaire, a physician at La Pitié-Salpêtrière Hospital in Paris, shares her perspective on evolving approaches in liver cancer care. Using the CHIEF data as a starting point, the discussion looks beyond the trial to reflect on how emerging evidence is interpreted in clinical practice. Dr. Allaire offers a thoughtful overview of key considerations, on...

Season 4 - Episode 2 In the second episode of ILCA’s Liver Cancer Podcast, hosted by Sarah Cappuyns, MD, PhD, a Gastroenterology resident and member of the Y-ILCA Committee, we are joined by Jeroen Dekervel, Digestive Oncologist at the University Hospital in Leuven, Belgium. In this episode, they engage in a discussion on the emerging role of biomarkers in guiding systemic therapy for hepatocellul...

Season 4 - Episode 1 In this new episode of ILCA’s Liver Cancer Podcast, we kick off our 2025 series with an insightful discussion on the latest advancements in hepatocellular carcinoma (HCC) surveillance. Hosted by Coskun Ozer Demirtas , Associate Professor of Gastroenterology & Hepatology at Marmara University (Turkey) and member of ILCA’s Young Investigators Committee, this episode features...

Season 3 - Episode 9 In this episode, sponsored by Roche, we delve into the groundbreaking findings from the IMbrave150 trial, focusing on the efficacy and safety of Atezolizumab plus Bevacizumab versus Sorafenib in patients with hepatocellular carcinoma (HCC) exhibiting main trunk and/or contralateral portal vein invasion. Join experts Amit Singal and Richard Finn as they break down the key resul...

Season 3 - Epiosode 8 In this episode, sponsored by Roche, David Pinato and Manon Allaire delve into the use of real-world research data and its implications. They share insights from their professional experiences with collecting, cleaning, and organizing this data. Clinical trial results often differ from real-world data, and our guests explore the gap between the two and its potential consequen...

Season 3 - Episode 7 In this episode, Joana Espírito Santo and Julien Calderaro explore the diagnostic complexity and the treatment and prognosis pitfalls of combined hepatocellular-cholangiocarcinomas (cHCC-CCAs). They reflect on the heterogeneity of these tumours and the potential impact of AI-based phenotyping, highlighting the importance of combining biopsy and imaging as an integrative approa...

Season 3 - Episode 6 In this episode, Lorenza Rimassa, Andrew Moon, and Jakob Kather discuss ways to enhance tumor board effectiveness. Lorenza emphasizes the importance of multidisciplinary collaboration, Andrew highlights patient representation, and Jakob explores the integration of AI. Listen to them as they engage in insightful exchanges, addressing questions and offering innovative solutions....

Season 3 -Episode 5 Meet Antonio D'Alessio and Claudia Campani, two of the best oral presenters from the ILCA 2023 Annual Conference. Antonio will present and discuss his work " Predictors of response to neoadjuvant immunotherapy in resectable hepatocellular carcinoma: preliminary clinical and translational analyses from the PRIME-HCC study ". Claudia will present her work " Dynamic evolution of c...

Season 3 - Episode 4 In this episode, Dr Taizo Hibi and Dr Cristina Dopazo discuss a recent review article in Hepatoma Research titled: “Liver Transplantation for perihiliar cholangiocarcinoma: Do we need to move forward?". They discuss the outstanding results of the Mayo Clinic protocol based on liver transplantation after neoadjuvant chemoradiation in very selected patients with unresectable de...

Season 3 - Episode 3 This episode discusses a recent review article in Hepatoma Research titled: "Challenges and Barriers in Hepatocellular Carcinoma Surveillance for Patients with non-alcoholic Fatty Liver Disease" (now called metabolic associated steatotic liver disease or MASLD). We discuss several important challenges and barriers that currently exist in caring for patients with MASLD cirrhosi...

In this episode, Drs. Maria Reig and Richard Finn will dive deep into the updates and groundbreaking research presented at the ASCO GI Meeting in January 2023. They will explore the latest advancements in the field of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). Here is what you can expect from this podcast: • Updates on the efficacy and safety of new drugs in HCC • The evolving la...

In this podcast, Lorenza Rimassa and Alejandro Forner summarize four abstracts orally presented during the ESMO annual congress held in Paris in September 2022. Three abstracts report the results of first-line phase 3 trials of immunotherapy for unresectable hepatocellular carcinoma, and one trial reports the results of a phase 1/2 trial of a new FGFR inhibitor for cholangiocarcinoma. HCC LEAP-002...

In this podcast, Valerie Paradis and Maria Barcena Varela discuss four different papers presented at ILCA AC 2022. These interesting works have the aim to combine experimental models and studies of clinical patients and identify new cellular target based on immune cells. This will help to predict the response to immune therapy and understand the prognosis of HCC.

In this episode David Pinato comments on the ILCA 2022 session on Diagnosis, Imaging and Biomarkers for HCC. Hear his considerations and analysis on novel biomarkers, protein biomarkers and gut microbiomes as potential sources of clinical available biomarkers in the setting of early diagnosis of liver cancers.

Medical education is key to improve liver surgery as well as preparing surgical procedures and setting technological tools in advance. In this podcast Gonzalo Sapisochin and Eric Vibert will go through the surgical session at ILCA2022, summarising and commenting on the future of liver surgery for primary liver cancer.

Hear all about the preliminary results of a real-life study, a new and promising therapeutical approach to HCC, the final results from FIGHT-202 and new presented data from the Phase 3 HIMALAYA Trial. In this episode, Associate Professor at Humanitas University and IRCCS Humanitas Research Hospital, Lorenza Rimassa, and Medical Doctor at BCLC group, Marco Sanduzzi Zamparelli, summarise the abstrac...

In this episode, Transplant Hepatologist at Royal Prince Alfred Hospital, Ken Liu, and Professor of Medicine at UT Southwestern Medical Center, Amit Singal, cover some of the highlights from the General Session 2: Epidemiology, Staging and Prognosis of HCC at the ILCA Annual Conference 2022. Join them as they discuss the latest data from the following abstracts: · Efficacy of Local Treatment in Ly...

Hepatocellular carcinoma is a major health problem worldwide, being the fifth most common cancer and the third among cancer-related deaths. Surgery represents the cornerstone treatment for early stages, and Minimally Invasive Liver Surgery (MILS) has become an attractive option thanks to reduced intraoperative blood losses, shortened length of hospital stay, and similar oncological outcomes when c...

In this episode, Drs. Amit Singal and Marco Sanduzzi-Zamparelli summarize presentations and the discussion from the ILCA Single Topic Workshop: HCC Risk Stratification and Surveillance , which was held in Paris, France on June 9-10, 2022. The meeting and podcast covered a variety of topics including: 1. Risk stratification, including emerging clinical and biomarker-based risk models 2. Current sta...

In this episode, authors Simone Khouzam and Duilio Pagano discuss the recently published research article " Protective benefit of minimally invasive liver surgery for hepatocellular carcinoma prior to transplant ". Examining the protective benefits of iterative surgical treatment of HCC prior to transplantation, surgeons at the ISMETT hospital in Palermo, Italy discuss the advantages of MILS for H...

Download full transcript here In this podcast, Alejandro Forner summarised and commented some selected abstracts at the EASL Liver Cancer Summit 2022 . The following abstracts will be discussed: 1. Regorafenib in patients with unresectable hepatocellular carcinoma in routine clinical practice: Exploratory analysis of safety and overall survival in the prospective, observational REFINE study. Finn...

In this Podcast Drs. Richard Finn and Mark Yarchoan review recent practice changing data from recent international meetings including ESMO Asia 2021 and ASCG GI 2022. These include results of the COSMIC 312 study, the HIMALAYA study, KEYNOTe 394 among others. Please join us for data review and some comments to put these results in context.

Read the full transcript here . In this podcast, co-chairs Lorenza Rimassa and Pierre Nahon summarised and commented the presentations during the plenary session Design of Clinical Trials for Adjuvant and Locoregional Strategies at the EASL Liver Cancer Summit 2022. Speakers: · Lorenza Rimassa, Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy · Pierre Nahon, Avicenne Hospit...

In this podcast, co-chairs Amit Singal and Nicole Rich summarised and commented the abstracts orally presented during the General Session 3: Diagnosis, Imaging and Biomarkers at the ILCA Annual Conference 2021. Speakers: · Amit Singal, MD, UT Southwestern Medical Center, USA · Nicole Rich, MD, MSCS , UT Southwestern Medical Center, USA

Download full transcript here In this podcast, co-chairs Amaia Lujambio and Stephanie Roessler summarised and commented the abstracts orally presented during the General Session 1: Molecular Pathogenesis, Cell Biology and Translational Research at the ILCA Annual Conference 2021. Speakers: · Amaia Lujambio, Icahn School of Medicine at Mount Sinai, New York · Stephanie Roessler, University of Heide...